Sustained Virologic Response Following a Shortened Course of Direct-Acting Antiviral Therapy in an HIV/HCV Co-Infected Patient With Previous Treatment Experience: A Case Report

We describe a 47-year-old treatment-experienced African-American man co-infected with human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV) who took sofosbuvir-velpatasvir-voxilaprevir (SOF/VEL/VOX) for approximately 4 weeks and achieved sustained virologic response 12 weeks post-treatment (SVR12). Prior to initiating SOF/VEL/VOX, the patient completed 10 weeks of treatment with SOF/VEL. After 1 month of SOF/VEL/VOX, the patient was lost to follow-up for 3 months. This case report illustrates that SVR12 may be achieved in treatment-experienced patients living with HIV/HCV who complete a shortened duration of triple-direct acting antiviral therapy. Healthcare professionals should consider obtaining an HCV-RNA to assess if SVR12 was achieved prior to re-initiating treatment in patients lost to follow-up or who did not complete therapy.